U.S. Diversified Financial Stock News

Jack Henry & Associates (JKHY) posted a 19.4% jump in earnings over the last year, far above its 7.5% average annual growth for the past five years. Net profit margins improved to 19.2%, compared to 17.2% a year earlier, highlighting a run of high-quality results. Though revenue and earnings are each expected to keep growing, future rates of 6.4% and 8.2% per year, respectively, trail behind broader US market forecasts. Despite a premium valuation compared to peers and the industry, strong...

California Resources (CRC) posted eye-catching results this quarter, with net profit margins jumping to 18.3%, up from 7.2% a year ago. Earnings rebounded 305.5% year-over-year, a major turnaround from the company’s five-year average decline of -25.6% annually. The share price sits at $46.27, well below an analyst fair value estimate of $114.76. This signals that investors are weighing strong profitability against looming concerns over slower revenue growth and projected earnings...

Curious whether Royalty Pharma is trading at a bargain, or if its recent performance signals something more? You are not alone. Valuation-focused investors have been eyeing this stock closely. After a strong run, Royalty Pharma’s shares are up 10.2% in the last week and 11.9% this month, racking up an impressive 56.7% gain year-to-date. Recent headlines have highlighted Royalty Pharma's aggressive moves in acquiring new royalty interests and expanding its biopharma portfolio. Both of these...

TD Cowen recently initiated analyst coverage on MBX Biosciences with a Buy rating, citing confidence in both the company’s validated PEP platform and the strong Phase II results for its lead asset, Canvuparatide, in hypoparathyroidism. The analyst also emphasized the significant market opportunity presented by MBX’s pipeline, supported by a management team considered to be highly capable within the biotechnology sector. We will explore how TD Cowen’s endorsement of MBX’s lead product and...

Wondering if uniQure’s rollercoaster stock price means it’s a bargain or a trap? Let’s dig into what’s really driving its value. uniQure shares have seen wild swings lately, dropping 63.1% in just the past week, but are still up an eye-catching 264.0% over the last year. This highlights both volatility and dramatic growth potential. Much of this action has been fueled by recent headlines about regulatory milestones for its gene therapy pipeline and an announced partnership set to expand its...

ACM Research (ACMR) is on track for robust growth, with revenue forecast to climb 15% per year, well ahead of the broader US market’s 10.5% annual growth. EPS is set to expand by 14.3% annually, net profit margins have increased to 13.8% from 12.3% last year, and earnings have averaged a 37% annual increase over the past five years. Investors may take notice as strong margin improvement and premium revenue growth continue to support a positive outlook, even as recent share price stability...

Curious if BWX Technologies might still be a great value, especially after its impressive run? Let's dig into the numbers and see what is actually going on beneath the surface. The stock soared 77.7% so far this year and is up an incredible 279.9% over the last five years. However, it did slip by 7.3% in the past week. There has been renewed attention following BWX Technologies' involvement in key defense contracts and growing demand for its nuclear solutions, which has fueled both optimism...

Curious if AbbVie's stock price actually matches its true value or if there's an opportunity hiding in plain sight? You are not alone. Let's dig into what really matters for long-term investors. It has been an eventful year for AbbVie, with the share price rising 20.8% year to date and up 11.5% over the last 12 months, despite a recent pullback of 5.8% in the past month. Investors have been buzzing about AbbVie's latest drug approvals and a steady stream of clinical trial updates. Recent...

United Fire Group (UFCS) delivered eye-catching results this year, with earnings surging 149.9% from a year ago and outpacing its own five-year annual earnings growth rate of 40.1%. Net profit margins rose to 6.9%, up from last year’s 3.2%. This reflects a solid uptrend in profitability while the company continues to grow earnings at a strong compounded annual pace. Investors now face the prospects of continued growth, high-quality earnings, and improved margins, balanced against valuation...

Niagen Bioscience (NAGE) posted annual revenue growth of 17.4%, beating the US market’s 10.5% pace. The bottom line also showed a significant turnaround, as the company turned profitable in the last year with a notable improvement in net profit margin. Earnings are now expected to grow at a rapid 41.2% per year over the next three years, compared to the broader market’s 16% growth estimate. Shares currently trade at $6.88, which is well below management’s internal fair value mark of $18.44...

Inogen (INGN) continues to face pressure on the bottom line, with losses rising at an annualized rate of 31.9% over the past five years and expectations set for ongoing unprofitability over the next three years. At the same time, revenue growth is forecast at just 6.2% per year, trailing the broader US market’s projected 10.5% pace. The company has not demonstrated any improvement in net profit margin during the last year. While the earnings outlook remains challenging, valuation metrics...

Hyster-Yale (HY) reported earnings shaped by a mix of standout historical growth and recent setbacks. Over the past five years, earnings have climbed at a 42.2% annual rate, but the latest period saw earnings dip due to a one-off $38.5 million loss. Net profit margins slipped to 0.6% from 4.1% last year, highlighting the recent profitability pressure. With revenue expected to grow at 2% per year and earnings forecast to accelerate at 31.7% annually, well above the U.S. market average,...

Tile Shop Holdings (TTSH) delivered another difficult quarter, with ongoing unprofitability and no progress in net profit margin over the past year. Losses have deepened at an average annual rate of 16.6% over the last five years, and shares currently trade at $6.37, well above an estimated fair value of $1.44. With no expectation of revenue or earnings growth on the horizon and a Price-To-Sales Ratio of 0.8x that looks stretched compared to sector benchmarks, investors have little near-term...

Curious if CorVel is still a buy at today’s prices? You’re not alone, especially with so much market noise surrounding the company’s true value. The stock has experienced noticeable ups and downs lately, with a 2.8% gain this past week but still down 30.9% year to date and 35.5% over the last year. This comes even after a solid 5-year climb of 147%. Recent headlines have spotlighted CorVel’s new technology partnerships and continued expansions into digital claims solutions, which have caught...

Curious whether Invesco is a bargain or just another overhyped financial stock? You're not alone; understanding its true value is on a lot of investors' minds right now. After climbing an impressive 32.4% so far this year, Invesco shares have pulled back slightly over the past month, reminding us that even strong performers experience volatility. Recent headlines have focused on industry shifts in asset management and changing investor flows, offering useful context for Invesco's price...

Safety Insurance Group, Inc. recently reported higher third quarter earnings, with revenue rising to US$326.62 million and net income reaching US$28.31 million, while also reaffirming a quarterly cash dividend of US$0.92 per share for shareholders in December 2025. A key insight is the company’s operational improvement shown by an improved combined ratio and plans to resume share repurchases, highlighting continued focus on shareholder value and financial discipline. We'll explore how Safety...

Sleep Number (SNBR) continues to face headwinds, reporting another year of rising losses, which have increased at an annual rate of 67.7% over the past five years. Despite a persistently negative net profit margin, the outlook has brightened with forecasts calling for annual earnings growth of 97.54% and a return to profitability within the next three years. This rate would outpace the broader market. Revenue is expected to grow at 3.6% per year, trailing the US average of 10.5%. However,...

Pursuit Attractions and Hospitality (PRSU) delivered third quarter results that defied expectations, reporting solid gains in both revenue and earnings at a time when analysts had been bracing for a meaningful drop. This surprise performance quickly grabbed investors’ attention. See our latest analysis for Pursuit Attractions and Hospitality. This earnings beat arrives after a stretch where the 1-year total shareholder return is down 15.3%, and the year-to-date share price return is still...

Wondering if FedEx stock could be an undervalued gem or if it’s already priced for perfection? Let’s dig into what the numbers tell us. FedEx shares have climbed 2.6% over the past week and 3.7% over the last month, but they are still down about 6.6% since the start of the year, hinting at a shifting balance between optimism and caution. Recently, FedEx garnered attention for ongoing cost-cutting initiatives and adjustments in delivery operations. These moves have helped reassure investors...

Trinity Capital (TRIN) delivered high quality earnings this period, with net profit margins rising to 54.4%, up from 41.8% a year ago. The company has been profitable over the past five years and recently reported an impressive 73.7% annual earnings growth rate, well ahead of its five-year average of 19.5%. While profitability trends remain strong, analysts are forecasting much slower growth ahead, with annual earnings expected to tick up just 0.2% and revenue to grow at 3.8%. This suggests a...

Par Pacific Holdings (PARR) remains unprofitable, but has managed to cut its losses at an impressive clip of 41.2% per year over the past five years. Investors are eyeing a projected 0.4% annual revenue decline over the next three years and continue to grapple with both negative net profit margins and ongoing poor earnings quality, as the company shows no signs of recent profitability to benchmark against previous years. With margins under pressure, the latest results set the stage for a key...

Berry (BRY) has become profitable over the past five years, reporting an average earnings growth of 41.6% per year. Looking ahead, earnings are expected to surge another 159.2% annually, but revenue is forecast to decline at an average pace of -1.1% per year for the next three years. The company also recorded a one-off loss of $3.9 million in the most recent financial year, tempering the near-term earnings outlook. Investors will be weighing this mix of rapid projected earnings growth and...

Scotts Miracle-Gro (SMG) reported earnings that finally swung into profitability over the last year, with EPS growth now forecast at 12.58% per year. Despite this turnaround, the company’s earnings have been on a tough path, declining at an average annual rate of 45.6% over the past five years. Recent results were impacted by a $136.1 million one-off loss. Revenue growth is expected to lag behind the broader market at 1.9% per year. Shares look expensive at a 60.9x price-to-earnings ratio...

Braemar Hotels & Resorts (BHR) remains unprofitable, with no improvement in its net profit margin over the last year. Over a five-year stretch, however, the company has steadily narrowed its losses at a rate of 7.3% per year. Revenue is forecast to grow at just 0.9% annually, compared to the broader US market’s projected 10.5% growth. In this operational context, BHR’s price-to-sales ratio of 0.2x stands out as especially low relative to both the industry and peers. The share price of $2.58...